Combination Therapy in Cancers With Mutations in DNA Repair Genes
NCT05694715 is a phase 1 interventional trial sponsored by University of California, San Francisco. As of 21 Nov 2026, it is active and no longer recruiting. It studies Irinotecan and Niraparib in ATM Gene Mutation, BRCA1 Mutation and 3 more conditions. The registry lists an enrollment of 24 participants at 1 site in 1 country. The registry lists a start date of 23 May 2023 and a primary completion date of 31 Aug 2028. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT05694715 |
| Status | Active not recruiting |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | University of California, San Francisco |
| Enrollment | 24 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | ATM Gene Mutation, BRCA1 Mutation, BRCA2 Mutation, Metastatic Solid Tumor and PALB2 Gene Mutation |
| Drugs | Irinotecan and Niraparib |
| Start | 23 May 2023 |
| Primary completion | 31 Aug 2028 |
| Study completion | 31 Aug 2028 |
| Last update posted | 12 Nov 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California, San Francisco
San Francisco
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT05694715
Each answer restates registry values shown on this page.
What is NCT05694715?
NCT05694715 is a phase 1 interventional trial sponsored by University of California, San Francisco. It studies Irinotecan and Niraparib in ATM Gene Mutation, BRCA1 Mutation and 3 more conditions.
Is NCT05694715 recruiting?
As of 21 Nov 2026, it is active and no longer recruiting.
Who leads NCT05694715?
The registry names Varun Monga, MBBS (principal investigator, University of California, San Francisco) as the overall official.
Where does NCT05694715 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT05694715 study?
The registered drug and biological interventions are Irinotecan and Niraparib.
When is NCT05694715 expected to complete?
The registry lists a primary completion date of 31 Aug 2028 and a study completion date of 31 Aug 2028. The sponsor last updated the record on 12 Nov 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.